GliaGenesis Ltd.
GliaGenesis develops therapies to promote brain regeneration for neuropsychiatric and neurodegenerative diseases. Using the Genes-to-Therapies pipeline, AI-driven multi-omics analysis and bioinformatic therapy screening, it identifies small molecules with known mechanisms of action. The company provides computational neuroscience analytics, including bulk and single-cell data analysis, powered by cloud-based data management and interpretation. Its drug discovery services, delivered as SaaS and research collaboration, target pharmaceutical research companies and emphasize clinician and industry partnerships to tailor treatments.
GliaGenesis Ltd.
GliaGenesis develops therapies to promote brain regeneration for neuropsychiatric and neurodegenerative diseases. Using the Genes-to-Therapies pipeline, AI-driven multi-omics analysis and bioinformatic therapy screening, it identifies small molecules with known mechanisms of action. The company provides computational neuroscience analytics, including bulk and single-cell data analysis, powered by cloud-based data management and interpretation. Its drug discovery services, delivered as SaaS and research collaboration, target pharmaceutical research companies and emphasize clinician and industry partnerships to tailor treatments.